Harnessing the immunological properties of stem cells as a therapeutic option for diabetic nephropathy

Acta Diabetologica

Volumn 51, Issue 6, 2014, Pages 897-904

  D’Addio, Francesca ^a,b   Trevisani, Alessio ^c   Ben Nasr, Moufida ^b   Bassi, Roberto ^a,b   El Essawy, Basset ^d   Abdi, Reza ^b   Secchi, Antonio ^a,e   Fiorina, Paolo ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d AL AZHAR UNIVERSITY   (Egypt)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Diabetic nephropathy; Stem cells; Type 1 diabetes; Type 2 diabetes

Indexed keywords

GAMMA INTERFERON; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT STEM CELL; ANTIINFLAMMATORY ACTIVITY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CORD BLOOD STEM CELL TRANSPLANTATION; DIABETIC NEPHROPATHY; EMBRYONIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; ADVERSE EFFECTS; ANIMAL; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HISTOCOMPATIBILITY; IMMUNOLOGY; STEM CELL;

ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION IMMUNOLOGY;

EID: 84919461730     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0603-1     Document Type: Review

References (74)

1. Williams WW et al (2012) Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes 61(8):2187–2194
2. Gross JL et al (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28(1):164–176
3. U.S. Renal Data System. USRDS 2010 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
4. Nathan DM et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353(25):2643–2653
5. National Kidney F (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–86
6. Astorri E et al (1997) Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment. Cardiology 88(2):152–155
7. Himmelfarb J, Tuttle KR (2013) New therapies for diabetic kidney disease. N Engl J Med 369(26):2549–2550
8. Paroni R et al (2005) Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids 28(4):389–394
9. Atkins RC, Zimmet P (2010) Diabetic kidney disease: act now or pay later. Acta Diabetol 47(1):1–4
10. Navarro-Gonzalez JF et al (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7(6):327–340
11. Macisaac RJ, Ekinci EI, Jerums G (2014) Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 63(2 Suppl 2):S39–S62
12. Galkina E, Ley K (2006) Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 17(2):368–377
13. Niewczas MA et al (2012) Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23(3):507–515
14. Mima A, Qi W, King GL (2012) Implications of treatment that target protective mechanisms against diabetic nephropathy. Semin Nephrol 32(5):471–478
15. Caramori ML et al (2002) Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 51(2):506–513
16. Fiorina P et al (2012) 31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients. Acta Diabetol 49(Suppl 1):S133–S139
17. Maffi P et al (2007) Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 30(5):1150–1155
18. Bennett WM, Henrich WL, Stoff JS (1996) The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 28(1 Suppl 1):S56–S62
19. Francese R, Fiorina P (2010) Immunological and regenerative properties of cord blood stem cells. Clin Immunol 136(3):309–322
20. Thomson JA et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147
21. Fiorina P, Voltarelli J, Zavazava N (2011) Immunological applications of stem cells in type 1 diabetes. Endocr Rev 32(6):725–754
22. Abdi R et al (2008) Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57(7):1759–1767
23. Bussolati B et al (2005) Isolation of renal progenitor cells from adult human kidney. Am J Pathol 166(2):545–555
24. Rojas-Rios P, Gonzalez-Reyes A (2014) The plasticity of stem cell niches: A general property behind tissue homeostasis and repair. Stem Cells 32(4):852–859
25. D’Addio F, VVA, Ben Nasr M, Franek E, Zhu D, Li L, Ning G, Snarski E, Fiorina P (2014) Autologous non-myeloablative hematopoietic stem cell transplantation in new onset type 1 diabetes: a multicenter analysis. Diabetes (in press)
26. Doria A, Niewczas MA, Fiorina P (2012) Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol 32(5):437–444
27. Fernandez-Real JM et al (2012) Structural damage in diabetic nephropathy is associated with TNF-alpha system activity. Acta Diabetol 49(4):301–305
28. Lim AK, Tesch GH (2012) Inflammation in diabetic nephropathy. Mediators Inflamm 2012:146–154
29. Abbate M, Zoja C, Remuzzi G (2006) How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17(11):2974–2984
30. RamachandraRao SP et al (2009) Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 20(8):1765–1775
31. Remuzzi G, Benigni A, Remuzzi A (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116(2):288–296
32. Yu CC et al (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369(25):2416–2423
33. Fiorina P et al (2014) Role of Podocyte B7-1 in Diabetic Nephropathy. J Am Soc Nephrol [Epub ahead of print]
34. Sharma K et al (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45(4):522–530
35. Lim AK et al (2009) Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 52(8):1669–1679
36. Kanamori H et al (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360(4):772–777
37. Adhikary L et al (2004) Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47(7):1210–1222
38. Sanchez AP, Sharma K (2009) Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med 11:e13
39. Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124(3):139–152
40. Okada S et al (2003) Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52(10):2586–2593
41. Lin M et al (2012) Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol 23(1):86–102
42. Drukker M et al (2002) Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA 99(15):9864–9869
43. Drukker M et al (2006) Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 24(2):221–229
44. Bonde S, Zavazava N (2006) Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients. Stem Cells 24(10):2192–2201
45. Fandrich F et al (2002) Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med 8(2):171–178
46. Blum B, Benvenisty N (2009) The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle 8(23):3822–3830
47. Little MH (2006) Regrow or repair: potential regenerative therapies for the kidney. J Am Soc Nephrol 17(9):2390–2401
48. Riolobos L et al (2013) HLA engineering of human pluripotent stem cells. Mol Ther 21(6):1232–1241
49. Cohen DE, Melton D (2011) Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet 12(4):243–252
50. Morigi M et al (2010) Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 28(3):513–522
51. Chang JW et al (2011) Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transpl 20(2):245–257
52. Masoad RE et al (2012) Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats. Pharmacol Rep 64(5):1223–1233
53. Gammaitoni L et al (2004) Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood 103(12):4440–4448
54. Romagnani P, Lasagni L, Remuzzi G (2013) Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol 9(3):137–146
55. Lin F (2008) Renal repair: role of bone marrow stem cells. Pediatr Nephrol 23(6):851–861
56. Romagnani P, Remuzzi G (2013) Renal progenitors in non-diabetic and diabetic nephropathies. Trends Endocrinol Metab 24(1):13–20
57. Chhabra P, Brayman KL (2009) The use of stem cells in kidney disease. Curr Opin Organ Transpl 14(1):72–78
58. Ezquer FE et al (2008) Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transpl 14(6):631–640
59. Zhou H et al (2009) Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin Med J (Engl) 122(21):2573–2579
60. Wang S et al (2013) Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transpl 19:538–546
61. Luz-Crawford P et al (2012) Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 7(9):e45272
62. Spaggiari GM et al (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111(3):1327–1333
63. Krampera M et al (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101(9):3722–3729
64. D’Addio F et al (2011) The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol 187(9):4530–4541
65. Guleria I et al (2007) Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 125(1):16–25
66. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815–1822
67. Fang Y et al (2012) Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int J Mol Med 30(1):85–92
68. Lee PY et al (2012) Induced pluripotent stem cells without c-Myc attenuate acute kidney injury via down-regulating the signaling of oxidative stress and inflammation in ischemia-reperfusion rats. Cell Transpl 21:2569–2585
69. Suarez-Alvarez B et al (2010) Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS One 5(4):e10192
70. Takahashi K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872
71. Taylor CJ, Bolton EM, Bradley JA (2011) Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci 366(1575):2312–2322
72. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676
73. Pera MF (2011) Stem cells: the dark side of induced pluripotency. Nature 471(7336):46–47
74. Liang J et al (2010) Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 69(8):1423–1429